Skip to main content
SpringerLink
Log in

Ruxolitinib treatment improves muscle mass in patients with myelofibrosis

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544

    Article  CAS  PubMed  Google Scholar 

  2. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798. https://doi.org/10.1056/NEJMoa1110556

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

none.

Author information

Authors and Affiliations

  1. Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000, Zagreb, Croatia

    Marko Lucijanic, Ena Soric, Martina Sedinic, Vlatko Pejsa & Rajko Kusec

  2. Hematology Department, University Hospital of Split, Split, Croatia

    Davor Galusic

  3. Radiology Department, University Hospital Dubrava, Zagreb, Croatia

    Marta Cubela & Renata Huzjan Korunic

  4. School of Medicine, University of Zagreb, Zagreb, Croatia

    Renata Huzjan Korunic, Vlatko Pejsa & Rajko Kusec

Authors
  1. Marko Lucijanic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davor Galusic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ena Soric
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martina Sedinic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marta Cubela
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renata Huzjan Korunic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vlatko Pejsa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rajko Kusec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marko Lucijanic.

Ethics declarations

Conflict of interest

ML, VP, and RK received speaker honoraria from Novartis.

Ethical statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the Institutional Review Boards.

Informed consent

Patients provided informed consent for molecular analyses.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lucijanic, M., Galusic, D., Soric, E. et al. Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol 100, 1105–1106 (2021). https://doi.org/10.1007/s00277-020-04243-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04243-8

Search

Navigation